NEW YORK, July 26, 2017 -- Stull, Stull & Brody (“SS&B”) announces that a class action lawsuit was commenced in the United States District Court for the Eastern District of Missouri on behalf of purchasers of stock of Mallinckrodt Public Limited Company’s (“Mallinckrodt”) (NYSE:MNK), between November 25, 2014 and January 18, 2017 (“Class Period”), in Mallinckrodt’s voluntary and contributory employee benefit plans. If you contributed money in any of Mallinckrodt’s voluntary employee benefit plans and acquired Mallinckrodt ADSs as a result of such contributions, your rights may be affected.
The complaint alleges, among other claims, that Mallinckrodt’s Registration Statement filed with the Securities and Exchange Commission violated Section 11 of the Securities Act of 1933 by omitting material facts and otherwise containing inaccurate, misleading and untrue statements of fact pertaining to, among other things, the long-term sustainability of Mallinckrodt’s revenues for HP Acthar Gel (“Acthar”), the only FDA-approved adrenocorticotropic hormone preparation. The action alleges that Acthar’s monopoly status was the product of unlawful anticompetitive practices and failed to disclose that its increasing reliance on Medicare and Medicaid meant that Mallinckrodt’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers.
If you purchased or acquired Mallinckrodt stock in any of the Company’s employee benefit plans during the Class Period and wish to serve as a lead plaintiff you may move the Court no later than September 22, 2017; however you must meet certain legal requirements. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Michael Klein, Esq. of SS&B at [email protected], telephone 212-687-7230 x147, or by fax to 212-490-2022.
SS&B has litigated class actions for violations of securities laws and breaches of fiduciary duty on behalf of defrauded investors over the past 40 years and has obtained court approval of substantial settlements on numerous occasions. SS&B has offices in New York and Beverly Hills. SS&B’s website (www.ssbny.com) has additional information about the firm.
Attorney advertising. Prior results do not guarantee a similar outcome. This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and ethical rules.


OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Britain Courts Anthropic Amid US Defense Department Dispute
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Apple Turns 50: From Garage Startup to AI Crossroads
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 



